ESTABLISHED SAFETY PROFILE
IN ADVANCED NSCLC

Selected ARs with a difference of ≥5% for all grades or ≥2% for Grade 3-4 toxicity between treatment groups
ABRAXANE® for advanced non-small cell lung cancer (NSCLC) selected adverse reactions from phase III trial - chart | Please see Important Safety Information located below ABRAXANE® for advanced non-small cell lung cancer (NSCLC) selected adverse reactions from phase III trial - chart | Please see Important Safety Information located below
  • a508 patients assessed in ABRAXANE/carboplatin-treated group.
  • b514 patients assessed in paclitaxel injection/carboplatin-treated group.
  • c513 patients assessed in paclitaxel injection/carboplatin-treated group.
  • dPeripheral neuropathy is defined by the MedDRA v14.0 SMQ neuropathy (broad scope).
  • MedDRA=Medical Dictionary for Regulatory Activities; SMQ=Standardized MedDRA Query.
  • a508 patients assessed in ABRAXANE/carboplatin-treated group.
  • b514 patients assessed in paclitaxel injection/carboplatin-treated group.
  • c513 patients assessed in paclitaxel injection/carboplatin-treated group.
  • dPeripheral neuropathy is defined by the MedDRA v14.0 SMQ neuropathy (broad scope).
  • MedDRA=Medical Dictionary for Regulatory Activities; SMQ=Standardized MedDRA Query.
  • Most Common Adverse Reactions

    ESTABLISHED SAFETY PROFILE
    IN ADVANCED NSCLC

    Common ARs (≥10%) for ABRAXANE + carboplatin observed at a similar incidence as with paclitaxel injection + carboplatin
    Common ARs (≥10%) for ABRAXANE + carboplatin observed at a similar incidence as with paclitaxel injection + carboplatin
    ABRAXANE® for advanced non-small cell lung cancer (NSCLC) most common adverse reactions from phase III trial - chart | Please see Important Safety Information located below ABRAXANE® for advanced non-small cell lung cancer (NSCLC) most common adverse reactions from phase III trial - chart | Please see Important Safety Information located below
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL